

## Jill Cataldi

---

**From:** Lisa Pomeroy <lisapomeroy@mindspring.com>  
**Sent:** Monday, May 17, 2021 11:45 AM  
**To:** Sen. Algieri, Dennis L.; Sen. Sosnowski, V. Susan; Sen. DiMario, Alana; Sen. Valverde, Bridget G.; Sen. Morgan, Elaine J.; Sen. Raptakis, Leonidas P.; Sen. Coyne, Cynthia A.; Sen. Anderson, Kendra; Sen. Calkin, Jeanine; Sen. McCaffrey, Michael J.; Sen. Miller, Joshua; Sen. Gallo, Hanna M.; Sen. Lombardi, Frank S.; Sen. Lombardo, Frank III; Sen. Murray, Melissa A.; Sen. de la Cruz, Jessica; Sen. Archambault, Stephen R.; Sen. Rogers, Gordon E.; Sen. Picard, Roger A.; Sen. Pearson, Ryan W.; Sen. Mendes, Cynthia M.; Sen. Paolino, Thomas J.; Sen. Acosta, Jonathon; Sen. Kallman, Meghan E.; Sen. Lawson, Valarie J.; Sen. Euer, Dawn; Sen. DiPalma, Louis P.; Sen. Seveney, James A.; Sen. Felag, Jr., Walter S.; Sen. Burke, John P.; Sen. Cano, Sandra; Sen. Ciccone III, Frank A.; Sen. Mack, Tiara T.; Sen. Bell, Samuel W.; Sen. Ruggiero, Dominick J.; Sen. Goldin, Gayle L.; Sen. Quezada, Ana B; Sen. Goodwin, Maryellen; Rep. Williams, Anastasia P.; Rep. Vella-Wilkinson, Camille; Rep. Tobon, Carlos E.; Rep. Tanzi, Teresa A.; Rep. Speakman, June; Rep. Solomon, Joseph J. Jr.; Rep. Lima, Steven J.; Rep. Slater, Scott; Rep. Shekarchi, K Joseph; Rep. Shanley, Evan P.; Rep. Shallcross Smith, Mary Ann; Rep. Serpa, Patricia A.; Rep. Ruggiero, Deborah; Rep. Roberts, Sherry; Rep. Ranglin-Vassell, Marcia R.; Rep. Quattrocchi, Robert J.; Rep. Price, Justin; Rep. Potter, Brandon C.; Rep. Place, David J.; Rep. Phillips, Robert D.; Rep. Perez, Ramon A.; Rep. O'Brien, William W.; Rep. Noret, Thomas E.; Rep. Newberry, Brian C.; Rep. Nardone, George A.; Rep. Morgan, Patricia L.; Rep. Morales, David; Rep. Messier, Mary; Rep. McNamara, Joseph M.; Rep. McLaughlin, James; Rep. McGaw, Michelle E.; Rep. McEntee, Carol Hagan; Rep. Marszalkowski, Alex; Rep. Lombardi, John J.; Rep. Lima, Charlene; Rep. Knight, Jason; Rep. Kislak, Rebecca M.; Rep. Kennedy, Brian Patrick; Rep. Kazarian, Katherine S.; Rep. Hull, Raymond A.; Rep. Henries, Brianna E.; Rep. Hawkins, Bernard A.; Rep. Handy, Arthur; Rep. Giraldo, Joshua J.; Rep. Fogarty, Kathleen A.; Rep. Filippi, Blake A.; Rep. Fenton-Fung, Barbara Ann; Rep. Fellela, Deborah A.; Rep. Felix, Leonela; Rep. Edwards, John G.; Rep. Donovan, Susan R; Rep. Diaz, Grace; Rep. Craven, Robert E.; Rep. Costantino, Gregory J.; Rep. Corvese, Arthur J.; Rep. Cortvriend, Terri-Denise; Rep. Chippendale, Michael W.; Rep. Cassar, Liana M.; Rep. Casimiro, Julie A.; Rep. Casey, Stephen M.; Rep. Carson, Lauren H.; Rep. Caldwell, Justine A.; Rep. Blazejewski, Christopher R.; Rep. Biah, Nathan W.; Rep. Bennett, David A.; Rep. Batista, Jose F.; Rep. Barros, Jean P.; Rep. Baginski, Jacquelyn M.; Rep. Azzinaro, Samuel A.; Rep. Amore, Gregg; Rep. Alzate, Karen; Rep. Ajello, Edith H.; Rep. Abney, Marvin L.; Rep. Ackerman, Mia A.  
**Subject:** Please support H6302  
**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

I am writing to ask you to support H6302 prohibiting businesses both private and state from requiring COVID-19 vaccination.

I am in strong opposition to mandating vaccination for the citizens of Rhode Island or anywhere in the US. At this point in time the available COVID vaccines are still under Emergency Use Authorization and do not yet have full FDA approval. Even the fact sheets distributed at the time of vaccination state that the "COVID-19 Vaccine has not undergone the same type of review as an FDA- approved or cleared product." When the EUA provision was added to the FDCA it included language under [21 U.S.C. § 360bbb-3\(e\)\(1\)\(A\)\(ii\)\(III\)](#) specifying that individuals must be informed "of the option to accept or refuse administration of the product, of the consequences, if any, of refusing administration of the product, and of the alternatives to the product that are available and of their benefits and risks."

Additionally, in reviewing the ever growing body of literature regarding the various COVID vaccines, I have concerns with mandating this vaccine in a population at very low risk of adverse outcome from natural infection. Israeli researchers have made the following statement: "At this stage, according to

preliminary findings, which need further corroboration, there is an impression of a higher number than expected, especially for ages up to the age of 30. A more advanced report on the subject will be prepared soon.” “The impression is that there is an increase in the incidence of the phenomenon especially in young men on the scale of 1:20,000 after vaccination. It is likely that the onset of myocarditis is associated with receiving the vaccine (especially the second dose).” There are ever increasing reports of adverse outcomes in younger populations in the VAERS database as well and the FDA currently has a backlog of cases for review.

There is absolutely no reason to mandate this vaccine and thus deprive our citizens of the right to make medical decisions for themselves and their families.

Sincerely,  
Lisa Pomeroy  
495 Stone Ridge Drive  
East Greenwich, RI 02818  
(401)480-2280